title: The next generation of antibody-drug conjugates comes of age.
authors.affiliation: Department of Physico-Chemistry, Centre d'Immunologie Pierre Fabre (CIPF), St Julien-en-Genevois 74164, France. alain.beck@pierre-fabre.com
authors.forename: Alain
authors.initials: A
authors.lastname: Beck
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Haeuw
authors.forename: Thierry
authors.initials: T
authors.lastname: Wurch
authors.forename: Liliane
authors.initials: L
authors.lastname: Goetsch
authors.forename: Christian
authors.initials: C
authors.lastname: Bailly
authors.forename: Nathalie
authors.initials: N
authors.lastname: Corvaïa
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates